The authors wish to retract the article entitled “Novel HSP90 InhibitorNVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells,” which was published in the May 15, 2013 (73:3062) issue of Cancer Research (1).
A University of Texas MD Anderson Cancer Center internal investigation has found that Dr. Jun Fu committed research misconduct as defined by 42 CFR Part 93 and MD Anderson's Research Misconduct Policy. Specifically, that Dr. Jun Fu falsified the data appearing in Figure 8B by modifying the death dates of mouse specimens to produce a fabricated survivability curve for GSC-11. Dr. Jun Fu has accepted full responsibility for this breach of research integrity. This constitutes a violation of MD Anderson policy concerning the ethical conduct of research, as well as a significant departure from the research practices commonly accepted by MD Anderson research community. Because of the severity of this breach of research integrity, the authors believe that retraction of the article represents the most appropriate course of action to ensure the accuracy of the scientific record.
The internal panel further concluded that none of the other co-authors of this article knew, or had reason to suspect that the data presented in the article had been manipulated by Dr. Jun Fu.
All co-authors have agreed to this retraction.
Dimpy Koul
Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Jun Yao
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer, Houston, Texas
Shuzhen Wang
Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Ying Yuan
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Erik Sulman
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Frederick Lang
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
W.K. Alfred Yung
Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Howard Colman
Department of Neurosurgery, Huntsman Cancer Hospital, Salt Lake City, Utah
RSS Feeds